Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

Clinical and Translational Oncology

Volumn 13, Issue 3, 2011, Pages 179-184

  Grávalos, Cristina ^a   Gómez Martín, Carlos ^a   Rivera, Fernando ^c   Alés, Inmaculada ^d   Queralt, Bernardo ^e   Márquez, Antonia ^f   Jiménez, Ulpiano ^g   Alonso, Vicente ^h   García Carbonero, Rocío ⁱ   Sastre, Javier ^j   Colomer, Ramon ^k   Cortés Funes, Hernán ^a   Jimeno, Antonio ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e HOSPITAL JOSEP TRUETA   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

ⁱ HOSPITAL SEVERO OCHOA   (Spain)

^j HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^k MD ANDERSON CANCER CENTER   (Spain)

more..

Author keywords

Adenocarcinoma; Gastric cancer; Gastroesophageal junction; HER2; Phase II; Trastuzumab

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEART ATRIUM FIBRILLATION; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; INJECTION SITE REACTION; INOPERABLE CANCER; LOWER ESOPHAGUS SPHINCTER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PROTEIN EXPRESSION; QUALITY OF LIFE; STOMACH ADENOCARCINOMA; TREATMENT DURATION;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; GENES, ERBB-2; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 79958202400     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0637-6     Document Type: Article

References (26)

1. Kelley JR, Duggan JM (2003) Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56:1-9 (Pubitemid 36183309)
2. Sastre J, García-Saenz JA, Díaz-Rubio E (2006) Chemotherapy for gastric cancer. World J Gastroenterol 12:2004-2213
3. Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909 (Pubitemid 46630593)
4. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712 (Pubitemid 19147683)
5. Kaptain S, Tan LK, Chen B (2001) Her-2/neu and breast cancer. Diagn Mol Pathol 10:139-152 (Pubitemid 32808108)
6. Yano T, Ochiai A, Doi T et al (2004) Expression of HER2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit. J Clin Oncol 22:14S(Abstr 4053)
7. Park DI, Yun JW, Park JH et al (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371-1379 (Pubitemid 44315804)
8. Kang YK, Bang YJ, Lordick F et al (2008) Incidence of gastric or gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity. Gastrointestinal Cancers Symposium p. 75 (abstr 11)
9. Tokunaga A, Onda M, Okuda T et al (1995) Clinical significance of epidermal growth factor (EGF), EGF receptor and c-erbB-2 in human gastric cancer. Cancer 75:1418-1425
10. Park DI, Yun JW, Park JH et al (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371-1379 (Pubitemid 44315804)
11. Yonemura Y, Ninomiya I, Yamaguchi A et al (1991) Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer. Cancer Res 51:1034-1038
12. Tanner M, Hollmen M, Junttila TT et al (2005) Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273-278 (Pubitemid 40309309)
13. Grávalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523-1529
14. Matsui Y, Inomata M, Tojigamori M et al (2005) Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 27:681-685
15. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H et al (2007) Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 59:795-805 (Pubitemid 46440603)
16. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
17. Ajani JA, Lee FC, Singh DA et al (2006) Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:663-667 (Pubitemid 46630431)
18. Ridwelski K, Gebauer T, Fahlke J et al (2001) Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 12:47-51 (Pubitemid 32162447)
19. Roth AD, Maibach R, Martinelli G et al (2000) Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Res (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11:301-306 (Pubitemid 30214667)
20. Ajani JA, Fodor MB, Tjulandin SA et al (2005) A multi-institutional phase II randomized trial of docetaxel plus cisplatin (DC) or DC plus 5-fluorouracil (DCF) in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660-5667
21. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24:4991-4997 (Pubitemid 46631401)
22. Colomer R, Montero S, Lluch A et al (2000) Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6:2356-2362 (Pubitemid 30399203)
23. Fornier MN, Seidman AD, Schwartz MK et al (2006) Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 16:234-239 (Pubitemid 40309302)
24. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687-697
25. Nicholas G, Cripps C, Au H-P et al (2006) Early results of a trial of trastuzumab, cisplatin and docetaxel for the treatment of metastatic gastric cancer overexpressing HER-2. ESMO abstr 1105
26. Rech J, Arnold D, Folprecht G et al (2006) A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer. ESMO abstr 1096